Adhera Therapeutics, Inc.

ATRX

ATRXAdhera Therapeutics, Inc. US flag

Other OTC

0.00

USD

- -

-1.17EPS

-NaNMarket Cap

Nov 25Next Earn

CIK

0000737207

ISIN

US00687E4061

CUSIP

00687E109

Return %

Stock

S&P500

-97.67

9.99

-99.99

59.68

-100.00

94.43

Use logarithmic scale

	2010 Y	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	TTM
Revenue per Share	280.02	70.67	62.86	24.97	4.06	5.17	- -	- -	0.14	0.46	- -	- -	- -	- -
Basic EPS, GAAP	-3,159.13	-929.93	-142.3	-18.55	-101.3	20.13	-3.53	-12.65	-32.88	-24.87	-9.76	-12.84	-0.92	-1.24
Free Cash Flow per Basic Share	-1,958.45	-509.47	-65.45	3.37	-38.8	-16.8	-2.2	-3.33	-17.87	-16.12	-1.08	-1.02	-0.61	-0.22
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	1,954.35	1.2	-83.89	-3,910.93	-2,741.17	-2,541.88	-8	-16.2	-47.58	-72.43	-81.91	-80.97	-24.15	-16.43
Tangible Book Value per Share	-633.47	-210.55	-183.77	-162.53	-89.88	-48.95	-11.18	-11.41	4.68	-18.24	-27.16	-38.35	-9.61	-7.21
Basic Weighted Avg Shares	- -	- -	- -	- -	- -	- -	- -	- -	1	1	1	1	2	4
Sales/Revenue/Turnover	2	2	4	2	- -	1	- -	- -	- -	- -	- -	- -	- -	- -
Operating Margin (%)	-1,057.07	-785.82	-147.07	-17.26	-704	-586.62	- -	- -	-13,972.37	-4,047.62	- -	- -	- -	- -
Depreciation Expense	2	1	1	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Net Income, GAAP	-28	-29	-10	-2	-6	3	-1	-6	-17	-12	-4	-6	-2	-4
Effective Tax Rate (%)	- -	- -	- -	- -	- -	0.05	- -	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	-1,128.17	-1,315.92	-226.37	-74.28	-1,295.4	490.74	- -	- -	-22,046.05	-4,753.17	- -	- -	- -	- -
Working Capital	-3	-2	-5	-5	1	-2	-3	-6	2	-10	-15	-25	-22	-26
LT Debt	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Equity	17	- -	-6	-7	-4	- -	3	- -	3	-10	-15	-25	-22	-26
Return on Invested Capital (%)	- -	- -	- -	- -	- -	198.76	- -	- -	- -	- -	- -	- -	- -	- -
Return on Capital (%)	- -	- -	- -	- -	- -	-0.99	- -	- -	- -	- -	- -	- -	- -	-21.85
Return on Common Equity (%)	- -	-342	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	- -	- -	- -
Net Income, GAAP	66.93%	14.85%	-66.71%
Free Cash Flow	-128.54%	102.99%	112.78%
Total Cash Common Dividend	- -	- -	- -
Total Equity	114.21%	44.59%	-11.63%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Andrew Albert Kucharchuk M.B.A.
Full Time Employees: 2
Sector: Healthcare
Industry: Biotechnology
Address: 8000 Innovation Parkway Baton Rouge LA United States of America 70820
IPO Date: Dec 7, 1993
CIK: 0000737207
Website: adherathera.com
Similar Companies: Jupiter Neurosciences, Inc. (JUNSW)
Bellicum Pharmaceuticals, Inc. (BLCM)
Generex Biotechnology Corporation (GNBTQ)
Carmell Therapeutics Corporation (CTCX)
ReNeuron Group plc (RNUGF)
3SBio Inc. (TRSBF)
Business: Adhera Therapeutics, Inc. focuses on the discovery and development of drugs. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

Company News

globenewswire.com
4 years ago
Manufacturing Commences on Adhera's MLR-1019 for Phase 2a Clinical Trial Treating Parkinson's Disease
investorplace.com
4 years ago
7 Biotech Penny Stocks With Huge Catalysts Coming in 2022
globenewswire.com
4 years ago
Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias

Year	Q1	Q2	Q3	Q4	FY
2021	-2.34	-0.88	-5.76	- -	-12.84
2022	-0.51	0.09	-0.57	- -	-0.92
2023	-0.29	0.08	-0.83	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2021	- -	- -	- -	- -	- -
2022	- -	- -	- -	- -	- -
2023	- -	- -	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2021	- -	- -	- -	- -	- -
2022	- -	- -	- -	- -	- -
2023	- -	- -	- -	- -	- -

	Mar'23	Jun'23	Sep'23
ST Debt	10	11	11
LT Borrowings	- -	- -	- -
LT Finance Leases	- -	- -	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	3	4	5
Market Capitalization	1	- -	- -

	2010 Y	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	TTM
Revenue per Share	280.02	70.67	62.86	24.97	4.06	5.17	- -	- -	0.14	0.46	- -	- -	- -	- -
Basic EPS, GAAP	-3,159.13	-929.93	-142.3	-18.55	-101.3	20.13	-3.53	-12.65	-32.88	-24.87	-9.76	-12.84	-0.92	-1.24
Free Cash Flow per Basic Share	-1,958.45	-509.47	-65.45	3.37	-38.8	-16.8	-2.2	-3.33	-17.87	-16.12	-1.08	-1.02	-0.61	-0.22
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	1,954.35	1.2	-83.89	-3,910.93	-2,741.17	-2,541.88	-8	-16.2	-47.58	-72.43	-81.91	-80.97	-24.15	-16.43
Tangible Book Value per Share	-633.47	-210.55	-183.77	-162.53	-89.88	-48.95	-11.18	-11.41	4.68	-18.24	-27.16	-38.35	-9.61	-7.21
Basic Weighted Avg Shares	- -	- -	- -	- -	- -	- -	- -	- -	1	1	1	1	2	4
Sales/Revenue/Turnover	2	2	4	2	- -	1	- -	- -	- -	- -	- -	- -	- -	- -
Operating Margin (%)	-1,057.07	-785.82	-147.07	-17.26	-704	-586.62	- -	- -	-13,972.37	-4,047.62	- -	- -	- -	- -
Depreciation Expense	2	1	1	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Net Income, GAAP	-28	-29	-10	-2	-6	3	-1	-6	-17	-12	-4	-6	-2	-4
Effective Tax Rate (%)	- -	- -	- -	- -	- -	0.05	- -	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	-1,128.17	-1,315.92	-226.37	-74.28	-1,295.4	490.74	- -	- -	-22,046.05	-4,753.17	- -	- -	- -	- -
Working Capital	-3	-2	-5	-5	1	-2	-3	-6	2	-10	-15	-25	-22	-26
LT Debt	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Total Equity	17	- -	-6	-7	-4	- -	3	- -	3	-10	-15	-25	-22	-26
Return on Invested Capital (%)	- -	- -	- -	- -	- -	198.76	- -	- -	- -	- -	- -	- -	- -	- -
Return on Capital (%)	- -	- -	- -	- -	- -	-0.99	- -	- -	- -	- -	- -	- -	- -	-21.85
Return on Common Equity (%)	- -	-342	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -

	Mar'23	Jun'23	Sep'23
Total Current Assets	- -	- -	- -
Accounts Receivable, Net	- -	- -	- -
Cash, Cash Equivalents & STI	- -	- -	- -
Inventories	- -	- -	- -
Total Current Liabilities	23	23	26
Payables & Accruals	8	8	9
ST Debt	10	11	11
Deferred Revenue	- -	- -	- -

Adhera Therapeutics, Inc.

Growth Rates

(avg. rate of change)

Company Description

Company News

Growth Rates

(avg. rate of change)

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year

Quarterly Revenue

Year

Capital Structure

Working Capital